Figure 4.
GBM survival prognostication using study’s principal component 2 (PC2), in the discovery and validation cohorts. Following principal component analysis (PCA) of 45 newly diagnosed GBM lymphocytic TME samples, PC2 was positively influenced by Th and CTL, and negatively by γδ-T and NK56. (A) KM survival curve shows survival extension for PC2low (below median) versus PC2high (above median) samples (P < .0001). PC2 scores were then calculated for TCGA GBM samples and optimal cutpoints were determined. (B) PC2 splits the survival curves of two CIBERSORT-derived TCGA GBM cohorts: all TCGA GBM patients (top) and TCGA GBM patients labeled as “treated” (bottom). (C) Nomogram for prognostication of newly diagnosed GBM patients who received chemoradiation therapy (N = 36), based on multivariate CPH model. GBM, glioblastoma multiforme, OS, overall survival, PC2, principal component 2, Mo., months, ECOG PS, Eastern Cooperative Oncology Group Performance Score. TME, tumor micro environment, Th, helper T cells, CTL, cytotoxic T lymphocytes, NK56, CD56 + natural killer cells, γδ-T, gamma-delta T cells, KM, Kaplan–Meier; TCGA, the cancer genome atlas; CPH, Cox proportional hazard.